Sorafenib-induced dermatologic Grade III toxicity: An important clinical manifestation

[8] Sorafenib acts by inhibiting growth of tumor and angiogenesis by inhibiting cell surface kinase receptors and intracellular Raf kinases (RAF/MEK/ERK, vascular endothelial growth factor receptor, and platelet-derived growth factor receptor). [...]the patient was started on oral sorafenib 200 mg BD with palliative intent. [8,9] According to BCLC staging treatment schedule, patients diagnosed with BCLC Stage A undergo hepatic resection/ablation can be the various treatment modalities of treatment; however, BCLC Stage B patients-TACE is the treatment option and advanced tumors with BCLC Stage C palliative therapy such as sorafenib or other oral tyrosine kinase inhibitors are the treatment options.